
|Videos|April 16, 2022
WATCH: A paradigm shift in the management of TED
Author(s)Andrew G. Lee, MD
Andrew Lee, MD, and Elizabeth Fortin, MD, discuss a paradigm shift in the treatment of thyroid eye disease with the new FDA approved medicine for managing TED.
Advertisement
In this week's discussion, Andrew Lee, MD, and Elizabeth Fortin, MD, disucss Teprotumumab, the first and only FDA approved medicine to treat thyroid eye disease (TED). They talk about the impact the drug can have on patients, cost considerations and how to use the treatment in the clinic.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
2
Thyroid eye disease specialists react to the FDA approval of veligrotug-vvze
3
Pterygium width may help predict corneal optical disturbance
4
Dry Eye Awareness Month: building a strong optometry-ophthalmology co-management model
5























